LARVOL Launches Platform to Curate Historical and Active Immuno-Oncology Clinical Trial Data in a Digital Dashboard
SAN FRANCISCO--(BUSINESS WIRE)--LARVOL, the leading provider of data and intelligence solutions for oncologists and the pharmaceutical and biotech industries, today announced the launch of CLIN, an easy-to-navigate platform that curates ten years of historical clinical trial data, with an initial focus on immuno-oncology.
Researchers, Medical Science Liaisons (MSLs), and oncologists can now access a complete database of more than 5,000 clinical trials and 20,000 documents, manually reviewed by experts, and coded to extract every table, graph, and figure. This SaaS platform allows cancer researchers and drug developers to search and analyze data across all clinical trials within a specific cancer type.
Additional benefits include:
Faster Curation: LARVOL’s team of experts manually review new trial data with speed and precision, posting results and exhibits in less than 24 hours so data is available in hours, not days. New data is added as it's released from publications, conferences, and guidelines.
Easier Searching: Detailed meta-tags make it easy to search, filter, and browse trial data by tumor type, drug, phase, endpoint, or even medical conference. The result is the most up-to-date repository of available oncology trial data available.
More Customizable: The user-friendly platform makes it easy to compare and extract historical data and customize per the user’s requirements with composite KM Curves and customizable forest plots.
“The future of improved cancer treatments lies, in part, in the ability to more quickly curate research and insights to provide researchers with access to the complete universe of clinical trial data. CLIN does just that,” said Bruno Larvol, CEO and Founder of LARVOL. “CLIN is an exciting next step in the innovative work LARVOL is doing to streamline the work of oncologists and researchers.”
CLIN was recently used to extract and analyze data for LARVOL’s poster presentation at the 2021 Virtual Meeting of the American Society of Clinical Oncologists (ASCO). The poster, titled “Control arm heterogeneity in trials for unselected advanced triple-negative breast cancer,” explored the application of CLIN in assessing heterogeneity in control arm time-to-event outcomes.
LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industries with expert curated information. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The VR-first, remote-always LARVOL team includes MDs, PhDs, and industry professionals around the globe who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.